Quick note as previous post got lost .
Agree with your number ( from a quick look )
So all 70,000 fistula procedures need the application of Von to generate your $166m in savings
How much can you charge per application then .
Re time to final abandonment. If this is improved by only 17% ( half previous trial ) but the ability to use the fistula in first year is increased by 30% ...how much can you charge for the drug.
Lots of moving parts assuming both end pts are stat sig....to determine what they can charge .
I'm apparently more concerned about the time to abandonment end pt then most .
The P value in the prior trial P.048 from memory tells me theres almost a 20% chance that the degree of benefit could be very different in the final trial....just my very basic understanding of bio stats.
My wife seems most concerned about time to abandonment , less on loss of primary patency ( blood flow ) as they apparently often do procedures to ensure proper blood flow .
Its when the fistula has to be abandoned ...thats the hard end pt
JMO
Kiwi
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM